-
Media ReleaseNew Novartis Phase III data for brolucizumab demonstrate reliability of 12-week treatment interval
-
Media ReleaseNovartis launches FocalView app, providing opportunity for patients to participate in ophthalmology clinical trials from home
-
Media ReleasePhase III data in The Lancet show Novartis siponimod significantly improved outcomes in patients with secondary progressive MS
-
Media ReleaseNovartis new data show Cosentyx® improved quality of life over 5 years in two thirds of patients with moderate to severe plaque psoriasis
-
Media ReleaseNovartis receives FDA approval for Cosentyx® label update to include moderate to severe scalp psoriasis
-
Media ReleaseNovartis new data reinforces superiority of Cosentyx® versus Stelara® in achieving skin clearance for psoriasis patients
-
Media ReleaseNovartis drug Promacta® receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA)
-
Media ReleaseNovartis Kisqali® received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer
-
Media ReleaseNovartis multiple sclerosis therapy fingolimod granted FDA Breakthrough Therapy designation for pediatric MS
-
Media ReleaseNovartis drug crizanlizumab shown to prolong time to patients' first sickle cell pain crisis in subgroup analysis of SUSTAIN study
-
Media ReleasePrimary analysis results from Novartis pivotal JULIET trial show Kymriah™ (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer
-
Media ReleaseNovartis initiates study evaluating impact of higher dosing of Cosentyx® in patients with ankylosing spondylitis